The final trades of the day with CNBC's Melissa Lee and the 'Fast Money' traders. Got a confidential news tip? We want to hear from you. Sign up for free newsletters and get more CNBC delivered to ...

I can't stand opening the Microsoft Store. It's slow to load, confusing to browse, and full of ads for things I don't care about. Luckily, thanks to a new feature, I don't have to open the Microsoft ...

On February 20, Barclays initiated coverage of Eli Lilly and Company (NYSE:LLY) with an Overweight rating. The firm set a $1,350 price target on the stock. The firm said GLP-1 weight loss treatments ...

Entering text into the input field will update the search result below Entering text into the input field will update the search result below ...

A rival just cut the price of a competing medication. This puts the list price of weight-loss drug Zepbound under pressure. That rival is Danish pharmaceutical company Novo Nordisk, best-known for its ...

Eli Lilly on Monday launched a new form of its blockbuster obesity drug, Zepbound, that offers a month's worth of doses in a single pen. The pen could serve as a more convenient option for some ...

Do you have an old Facebook account that you're no longer using, with posts or pictures from your younger days that you don't want people to see? It's easy to delete your Facebook account if you still ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

Eli Lilly & Co. engages in the discovery, development, manufacture, and sale of pharmaceutical products. The firm's products consist of diabetes, oncology, immunology, neuroscience, and other products ...

Eli Lilly & Co. engages in the discovery, development, manufacture, and sale of pharmaceutical products. The firm's products consist of diabetes, oncology, immunology, neuroscience, and other products ...